Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CSH71
- Development stage
- Preclinical
- Lead developer
- City of Hope Beckman Research Institute
01
Overview
CSH71: sourced facts only. name: "To counter this effect, we evaluated a dual-targeting strategy combining the p38β inhibitor Nilotinib with p38γ inhibitors F7 (ATP-site) and CSH71 (ligand-binding-domain site)." [DOI:10.1158/1538-7445.am2026-1001]; target: "To counter this effect, we evaluated a dual-targeting strategy combining the p38β inhibitor Nilotinib with p38γ inhibitors F7 (ATP-site) and CSH71 (ligand-binding-domain site)." [DOI:10.1158/1538-7445.am2026-1001]; developer: "Beckman Research Institute of The City of Hope, Duarte, CA." [DOI:10.1158/1538-7445.am2026-1001]; stage: "In Hut78 CTCL cells, combined F7 + CSH71 treatment significantly reduced cell viability with strong synergy (31.25 nM F7 + 1.25 μM CSH71; CI = 0.69)." [DOI:10.1158/1538-7445.am2026-1001]
02
Targets
MAPK12 (Mitogen-activated protein kinase 12)
Beyond the preview
Go deeper on CSH71.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CSH71.